|
| 36196060 | Association of time-to-intravenous furosemide with mortality in acute heart failure: data from REPORT-HF. | Eur J Heart Fail | 2023 |
| 36974770 | Impact of left ventricular ejection fraction phenotypes on healthcare resource utilization in hospitalized heart failure: a secondary analysis of REPORT-HF. | Eur J Heart Fail | 2023 |
| 34516969 | A global perspective of racial differences and outcomes in patients presenting with acute heart failure. | Am Heart J | 2022 |
| 35429091 | Quality of life assessed 6â¿¿months after hospitalisation for acute heart failure: an analysis from REPORT-HF (international REgistry to assess medical Practice with lOngitudinal obseRvation for Treatment of Heart Failure). | Eur J Heart Fail | 2022 |
| 35393622 | Global disparities in prescription of guideline-recommended drugs for heart failure with reduced ejection fraction. | Eur Heart J | 2022 |
| 35064730 | Regional differences in precipitating factors of hospitalization for acute heart failure: insights from the REPORT-HF registry. | Eur J Heart Fail | 2022 |
| 35175352 | Rationale and design of two trials assessing the efficacy, safety, and tolerability of inclisiran in adolescents with homozygous and heterozygous familial hypercholesterolaemia. | Eur J Prev Cardiol | 2022 |
| 33839078 | Global Differences in Burden and Treatment of Ischemic Heart Disease in Acute Heart Failure: REPORT-HF. | JACC Heart Fail | 2021 |
| 32710857 | Correction to: Post-discharge prognosis of patients admitted to hospital for heart failure by world region, and national level of income and income disparity (REPORT-HF): a cohort study. | Lancet Glob Health | 2020 |
| 32087174 | Post-discharge prognosis of patients admitted to hospital for heart failure by world region, and national level of income and income disparity (REPORT-HF): a cohort study. | Lancet Glob Health | 2020 |
| 31913404 | Global Differences in Characteristics, Precipitants, and Initial Management of Patients Presenting With Acute Heart Failure. | JAMA Cardiol | 2020 |
| 27574437 | Blood pressure and fasting lipid changes after 24 weeks' treatment with vildagliptin: a pooled analysis in >2,000 previously drug-naïve patients with type 2 diabetes mellitus. | Vasc Health Risk Manag | 2016 |
| 25754836 | International REgistry to assess medical Practice with lOngitudinal obseRvation for Treatment of Heart Failure (REPORT-HF): rationale for and design of a global registry. | Eur J Heart Fail | 2015 |
| 26250051 | Cardiovascular and heart failure safety profile of vildagliptin: a meta-analysis of 17â¿¿000 patients. | Diabetes Obes Metab | 2015 |
| 26587020 | Four-Point Preprandial Self-Monitoring of Blood Glucose for the Assessment of Glycemic Control and Variability in Patients with Type 2 Diabetes Treated with Insulin and Vildagliptin. | Int J Endocrinol | 2015 |
| 26067186 | Comparison of vildagliptin and sitagliptin in patients with type 2 diabetes and severe renal impairment: a randomised clinical trial. | Diabetologia | 2015 |
| 25664602 | Effect of vildagliptin on hepatic steatosis. | J Clin Endocrinol Metab | 2015 |
| 25783754 | Is There Evidence of Any Safety Differences Among DPP-4 Inhibitors in the Treatment of People with Type 2 Diabetes Mellitus and Reduced GFR Due to Chronic Kidney Disease? | Diabetes Ther | 2015 |
| 24391442 | Experience with DPP-4 inhibitors in the management of patients with type 2 diabetes fasting during Ramadan. | Vasc Health Risk Manag | 2014 |
| 25429228 | Changes in body weight after 24 weeks of vildagliptin therapy as a function of fasting glucose levels in patients with type 2 diabetes. | Vasc Health Risk Manag | 2014 |
| 25230877 | Higher Risk of Hypoglycemia with Glimepiride Versus Vildagliptin in Patients with Type 2 Diabetes is not Driven by High Doses of Glimepiride: Divergent Patient Susceptibilities? | Diabetes Ther | 2014 |
| 24920915 | A double-blind, randomized trial, including frequent patient-physician contacts and Ramadan-focused advice, assessing vildagliptin and gliclazide in patients with type 2 diabetes fasting during Ramadan: the STEADFAST study. | Vasc Health Risk Manag | 2014 |
| 24612221 | Glucagon dynamics during hypoglycaemia and food-re-challenge following treatment with vildagliptin in insulin-treated patients with type 2 diabetes. | Diabetes Obes Metab | 2014 |
| 24682379 | Efficacy of vildagliptin versus sulfonylureas as add-on therapy to metformin: comparison of results from randomised controlled and observational studies. | Diabetologia | 2014 |
| 23538267 | Vildagliptin more effectively achieves a composite endpoint of HbAâ¿c < 7.0% without hypoglycaemia and weight gain compared with glimepiride after 2 years of treatment. | Diabetes Res Clin Pract | 2013 |
| 23821355 | Experience with vildagliptin in patients â¿¥75Â years with type 2 diabetes and moderate or severe renal impairment. | Diabetes Ther | 2013 |
| 23680741 | Combination therapy with DPP-4 inhibitors and insulin in patients with type 2 diabetes mellitus: what is the evidence? | Hosp Pract (1995) | 2013 |
| 23431062 | Clinical evidence and mechanistic basis for vildagliptin's effect in combination with insulin. | Vasc Health Risk Manag | 2013 |
| 23378769 | Efficacy of vildagliptin in combination with insulin in patients with type 2 diabetes and severe renal impairment. | Vasc Health Risk Manag | 2013 |
| 22051153 | Effects of vildagliptin on postprandial markers of bone resorption and calcium homeostasis in recently diagnosed, well-controlled type 2 diabetes patients. | J Diabetes | 2012 |
| 22736406 | Impact of insulin resistance, body mass index, disease duration, and duration of metformin use on the efficacy of vildagliptin. | Diabetes Ther | 2012 |
| 22855332 | Vildagliptin reduces glucagon during hyperglycemia and sustains glucagon counterregulation during hypoglycemia in type 1 diabetes. | J Clin Endocrinol Metab | 2012 |
| 22875195 | Cancer outcomes and all-cause mortality in adults allocated to metformin: systematic review and collaborative meta-analysis of randomised clinical trials. | Diabetologia | 2012 |
| 22661900 | Evidence to support the use of vildagliptin monotherapy in the treatment of type 2 diabetes mellitus. | Vasc Health Risk Manag | 2012 |
| 22615074 | Incretin therapies in the management of patients with type 2 diabetes mellitus and renal impairment. | Hosp Pract (1995) | 2012 |
| 21239518 | Inhibition of DPP-4 with vildagliptin improved insulin secretion in response to oral as well as "isoglycemic" intravenous glucose without numerically changing the incretin effect in patients with type 2 diabetes. | J Clin Endocrinol Metab | 2011 |
| 22127800 | Minimizing the risk of hypoglycemia with vildagliptin: Clinical experience, mechanistic basis, and importance in type 2 diabetes management. | Diabetes Ther | 2011 |
| 21547496 | Beta cell function following 1 year vildagliptin or placebo treatment and after 12 week washout in drug-naive patients with type 2 diabetes and mild hyperglycaemia: a randomised controlled trial. | Diabetologia | 2011 |
| 21733061 | Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: a prospective 24-week randomized placebo-controlled trial. | Diabetes Obes Metab | 2011 |
| 21441754 | Incretin therapies in the management of elderly patients with type 2 diabetes mellitus. | Hosp Pract (1995) | 2011 |
| 21507182 | Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans. | Diabetes Obes Metab | 2011 |
| 21415917 | Assessing the general safety and tolerability of vildagliptin: value of pooled analyses from a large safety database versus evaluation of individual studies. | Vasc Health Risk Manag | 2011 |
| 21114604 | Clinical experience with vildagliptin in the management of type 2 diabetes in a patient population â¿¥75 years: a pooled analysis from a database of clinical trials. | Diabetes Obes Metab | 2011 |
| 20441397 | Role of vildagliptin in managing type 2 diabetes mellitus in the elderly. | Curr Med Res Opin | 2010 |
| 20518805 | An assessment of adverse effects of vildagliptin versus comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function from a large pooled database of Phase II and III clinical trials. | Diabetes Obes Metab | 2010 |
| 20518804 | Assessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large Phase III type 2 diabetes population. | Diabetes Obes Metab | 2010 |
| 19174497 | Vildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with type 2 diabetes. | J Clin Endocrinol Metab | 2009 |
| 19476473 | Comparison of vildagliptin and metformin monotherapy in elderly patients with type 2 diabetes: a 24-week, double-blind, randomized trial. | Diabetes Obes Metab | 2009 |
| 19089382 | Experimental infection of rodent mammals for fungal virulence testing. | Methods Mol Biol | 2009 |
| 18093207 | Robust improvements in fasting and prandial measures of beta-cell function with vildagliptin in drug-naïve patients: analysis of pooled vildagliptin monotherapy database. | Diabetes Obes Metab | 2008 |